228 Antigen specific active immunotherapy for ovarian cancer

Antigen specific active immunotherapy: lessons from the first decade.

Malignant melanoma is a tumour with a steeply rising incidence and scarce therapeutic options once metastatic. Approximately 1200 new cases are reported yearly in Switzerland with roughly 220 deaths/year. An important particularity of melanoma is its immunogenicity, which has long been recognized and investigated using various clinical immunization protocols in the last fifty years. The year 19...

Immunotherapy for Breast Cancer Treatment

Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...

Active specific immunotherapy for solid tumours

Future Directions for Immunotherapy in Ovarian Cancer

Immunotherapies involving cellular and checkpoint inhibitor approaches are under investigation in ovarian cancer and preliminary results suggest evidence of clinical benefit. Assumptions in the past of low immunogenicity of ovarian cancer appear to be changing as our new awareness of immune function activity with ovarian cancer, tumor microenvironment and molecular signaling is becoming evident...

Adoptive immunotherapy against ovarian cancer

The standard front-line therapy for epithelial ovarian cancer (EOC) is combination of debulking surgery and platinum-based chemotherapy. Nevertheless, the majority of patients experience disease recurrence. Although extensive efforts to find new therapeutic options, cancer cells invariably develop drug resistance and disease progression. New therapeutic strategies are needed to improve prognosi...